Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I.
A 4-h posttreatment with 4 microM beta-lapachone was previously shown to enhance the lethality of X-rays against human laryngeal epidermoid carcinoma (HEp-2) cells (D. A. Boothman et al., Cancer Res., 47:5361-5366, 1988). We now show that beta-lapachone (a) activates the DNA-unwinding activity of topoisomerase I, (b) inhibits the fast component of potentially lethal damage repair (PLDR) carried out by HEp-2 cells when present during or immediately following X-irradiation, (c) specifically and synergistically enhances the cytotoxic effects of DNA-damaging agents which induce DNA strand incisions, such as neocarzinostatin or X-rays, against a radioresistant human malignant melanoma (U1-Mel) cell line, (d) does not synergistically potentiate melphalan-induced lethality against U1-Mel cells but inhibits survival recovery and increases sister chromatid exchanges, and (e) does not further enhance the lethal effects of X-rays following prolonged drug exposures, indicating that beta-lapachone modifies initially created DNA lesions or inhibits lesion repair but does not create lethal lesions by itself. beta-Lapachone accelerated the DNA-unwinding activity of topoisomerase I derived from avian erythrocytes, calf thymus, or HEp-2 cells. beta-Lapachone did not intercalate into DNA, nor did it inhibit topoisomerase II or ligation carried out by mammalian or T4 DNA ligases. Structurally similar analogues, alpha-lapachone, lapachol, and dichloroallyl lawsone, did not enhance X-ray-induced cytotoxicity nor did they activate topoisomerase I. Camptothecin, a specific inhibitor of topoisomerase I, significantly radiosensitized HEp-2 cells, in a manner similar to beta-lapachone. These results suggest a role of topoisomerase I in DNA repair. The PLDR capacity of confluent-arrested HEp-2 cells was inhibited when beta-lapachone was given immediately following or during X-irradiation. The effect decreased when the drug was added at later times. beta-Lapachone may enhance lethality by converting single- into double-stranded DNA breaks during PLDR or through DNA conformational changes which inhibit PLDR. We propose that either mechanism of enhanced lethality may result from the ability of beta-lapachone to activate topoisomerase I.
Boothman
D A
DA
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115.
Trask
D K
DK
Pardee
A B
AB
D000818:Animals; D002645:Chickens; D004249:DNA Damage; D004260:DNA Repair / Q000187:drug effects*; D004264:DNA Topoisomerases, Type I / Q000378:metabolism*; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004789:Enzyme Activation; D006801:Humans; D007700:Kinetics; D009285:Naphthoquinones / Q000494:pharmacology*; D013997:Time Factors
D009285:Naphthoquinones; C014638:beta-lapachone; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II